A recent poll conducted by the Pistoia Alliance highlights significant barriers to AI adoption in clinical trials, with trust and regulatory uncertainty being the primary concerns for 50% of respondents. This survey was part of the Clinical Trials Technology Congress in London, where discussions centered on how regulators are prepared to collaborate with pharmaceutical companies to ensure the safe and compliant integration of AI technologies.
At the Congress, regulators from various agencies expressed their willingness to embrace AI, emphasizing the necessity for pharma companies to engage with them early in the process. The consensus was that while speed is essential, it must not compromise patient safety. For AI to be effectively integrated into clinical development, the industry requires validated and explainable methodologies rather than opaque models, which could create confusion for both sponsors and regulators. The Pistoia Alliance aims to facilitate this collaboration by bringing together stakeholders to develop common frameworks.
The poll also indicated that AI is starting to show value in clinical development, with 42% of participants reporting early signs of Return on Investment (ROI). Respondents anticipate that AI will significantly impact data cleaning, analysis, and patient engagement over the next few years. Zahid Tharia, a director at Open Pharma Research, noted that as more AI-discovered therapies emerge, the competition for trial sites and patient populations intensifies, underscoring AI's potential to alleviate these challenges.
Additionally, the poll revealed that 60% of respondents are utilizing or exploring patient-generated data, including insights from social media, to enhance clinical development. This approach is seen as vital for understanding patient needs and experiences. Thierry Escudier from the Pistoia Alliance emphasized the importance of ethically and systematically collecting such data to further patient-centered drug development. The Alliance is actively developing best-practice frameworks for the ethical use of social media data and is encouraging pharma companies to contribute to future projects in this area.